Ministry of Health and Family Welfare
Recovery of more than 20,000 cases in the last 24 hours pushes the Recovery Rate to 63.24%
Recovered Cases close to 6 lakhs
Actual Case Load of COVID-19 is only 3,19,840 active cases
Posted On: 15 JUL 2020 5:35PM by PIB Delhi
The last 24 hours have seen a sharp rise in the number of COVID-19 patients recovering. 20,572 people were cured which has taken the total number of recovered cases among COVID-19 patients to 5,92,031. The recovery rate has climbed up to 63.24% today.
The surge in recovered cases is driven by aggressive testing, timely diagnosis and effective management of the patients either through supervised home isolation or under active medical attention in the hospitals. The actual case load of COVID-19 is only 3,19,840 active cases. They are all under medical supervision. The norms and standards for Home Isolation along with use of oxymeters have helped to keep a check on the asymptomatic or mildly symptomatic patients without putting pressure on the hospital infrastructure.
The gap between recovered and active cases has been consistently growing. It stands at 2,72,191 today. The number of recovered cases outweighs the active cases by a factor of 1.85.
Medical infrastructure in India to treat COVID-19 patients includes 1378 Dedicated COVID Hospitals (DCH), 3077 Dedicated COVID Health Centres (DCHC), and 10351 COVID Care Centres (CCC). They have a total of 21,738 ventilators, 46,487 ICU beds, and 1,65,361 Oxygen beds to treat COVID-19 patients.
The Central government has distributed 230.98 lakhs N95 masks, 123.56 lakhs PPEs and 11,660 ventilators to States/UTs/Central institutions to ensure effective clinical management of COVID-19.
For all authentic & updated information on COVID-19 related technical issues, guidelines & advisories please regularly visit: https://www.mohfw.gov.in/ and @MoHFW_INDIA .
Technical queries related to COVID-19 may be sent to technicalquery.covid19@gov.in and other queries on ncov2019@gov.in and @CovidIndiaSeva .
In case of any queries on COVID-19, please call at Ministry of Health & Family Welfare helpline no.: +91-11-23978046 or 1075 (Toll-free). List of helpline numbers of States/UTs on COVID-19 is also available at https://www.mohfw.gov.in/pdf/coronvavirushelplinenumber.pdf .
MV/SG
(Release ID: 1638792) Visitor Counter : 190
Ministry of Health and Family Welfare
WHO advises 140 tests/day/million population
22 States/UTs in India are already conducting 140 and more tests/day/ million
Testing per million crosses 8994
22 States/UTs in India are already conducting 140 and more tests/day/ million
Testing per million crosses 8994
Posted On: 15 JUL 2020 12:59PM by PIB Delhi
WHO in its Guidance Note on “Public Health Criteria
to Adjust Public Health and Social Measures in the Context of COVID-19” has
advised comprehensive surveillance for suspected cases. While explaining the
concept of comprehensive surveillance and testing of suspect cases, WHO advises
that a country needs 140 tests per day per million population.
With the various coordinated efforts made by the
Centre and the States/UTs, 22 States/UTs in India are already conducting 140
and more tests per day per million. States/UTs are being regularly advised to
increase the testing capacity to match the WHO advised levels of testing.
One of the factors strongly aiding the increasing
numbers of COVID-19 tests in the country is the steadily growing network of
labs for testing of COVID-19. With 865 labs in the government sector and 358
private labs, the total number of testing labs is 1223, as on date. In addition
to the gold standard for test, RT PCR, TrueNat and CBNAAT are also used to
augment this facility.
• Real-Time RT PCR based testing
labs: 633 (Govt: 391 + Private: 242)
• TrueNat based testing labs: 491
(Govt: 439 + Private: 52)
• CBNAAT based testing labs: 99
(Govt: 35 + Private: 64)
The expansion of laboratory capacity has seen
exponential increase from one lab in Jan 2020 to 121 labs in March 2020 and to
1223 labs today.
During the last 24 hours 3,20,161 samples have been
tested. The cumulative number of samples tested, as of now is 1,24,12,664. The
testing per million for India is consistently rising. Today it has touched
8994.7. On 14th July 2020, more than 3.2 lakh tests were done on a single day.
For all authentic & updated information on
COVID-19 related technical issues, guidelines & advisories please regularly
visit: https://www.mohfw.gov.in/ and @MoHFW_INDIA.
Technical queries related to COVID-19 may be sent
to technicalquery.covid19@gov.in and other queries on ncov2019@gov.in and @CovidIndiaSeva
.
In case of any queries on COVID-19, please call at
the Ministry of Health & Family Welfare helpline no.: +91-11-23978046 or
1075 (Toll-free). List of helpline numbers of States/UTs on COVID-19 is also
available at https://www.mohfw.gov.in/pdf/coronvavirushelplinenumber.pdf .
****
MV/SG
(Release ID: 1638696) Visitor Counter : 497
Ministry of Health and Family Welfare
Market approval for Pneumococcal Polysaccharide
Conjugate Vaccine given by DCGI
Posted On: 15 JUL 2020 3:13PM by PIB Delhi
Drug Controller General of India (DCGI) has given
approval to the first fully indigenously developed Pneumococcal Polysaccharide
Conjugate Vaccine. This vaccine has been developed by M/s. Serum Institute of
India Pvt. Ltd, Pune. Serum Institute first obtained the approval of DCGI to
conduct Phase I, Phase II and Phase III clinical trials of Pneumococcal
Polysaccharide Conjugate Vaccine in India. These trials have since been
concluded within the country. The said Company has also conducted these
clinical trials in another country i.e. Gambia.
Thereafter, the said Company applied for approval
and permission to manufacture this vaccine. The application along with the
clinical trial data has been reviewed by the Office of Drug Controller General
of India with the help of Special Expert Committee (SEC) for vaccines.
The Committee recommended for grant of permission of market authorization to
the said vaccine. On 14/07/2020, M/s. Serum Institute of India Pvt. Ltd, Pune
has been granted permission to manufacture domestically developed first
Pneumococcal Polysaccharide Conjugate Vaccine. This is the first indigenously
developed vaccine in the field of pneumonia. Earlier the demand of such vaccine
was substantially met by licensed importers in the country since the
manufacturers were all vaccine companies based outside India.
This vaccine is used for active immunization
against invasive disease and pneumonia caused by “Streptococcus pneumonia” in
infants. The vaccine is administered in a intramuscular manner.
****
MV
(Release ID: 1638731) Visitor Counter : 506
No comments:
Post a Comment